Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Synapse Project

NCT: NCT04871074 · COMPLETED

NCT IDNCT04871074
StatusCOMPLETED
Start Date2018-11-18
Completion2025-05-01
SponsorUniversity of Wisconsin, Madison (OTHER)
First posted
Last updated

Brief Summary

The overarching goal of this project is to use \[C-11\]UCB-J to obtain spatial information on neuronal synapse abundance and inform Alzheimer's disease (AD) progression. The investigators propose to collect longitudinal amyloid, tau, and Synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) in participants in the Wisconsin Alzheimer's Disease Research Center (ADRC) and Wisconsin Registry for Alzheimer's Prevention (WRAP) across the clinical stages of AD, including cognitively unimpaired biomarker negative, unimpaired biomarker positive, mild cognitive impairment (MCI), and dementia due to AD.

Frequently Asked Questions

What is The Synapse Project?

The Synapse Project is a clinical trial registered under NCT04871074. Current status: COMPLETED.

What is the status of NCT04871074?

The current status of NCT04871074 (The Synapse Project) is: COMPLETED.

When did The Synapse Project start?

The Synapse Project started on 2018-11-18.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.